Potential Therapeutic Effects of Ritanserin in Cushing’s Disease

JAMA: The Journal of the American Medical Association

Volumn 267, Issue 8, 1992, Pages 1073-

  Sonino, Nicoletta ^a   Boscaro, Marco ^a   Fallo, Francesco ^a   Fava, Giovanni A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; RITANSERIN;

ADULT; CASE REPORT; CORTICOTROPIN RELEASE; CUSHING DISEASE; FEMALE; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; HYPOPHYSIS ADENOMA; LETTER; PRIORITY JOURNAL;

CASE REPORT; CUSHING SYNDROME; FEMALE; HUMAN; MIDDLE AGE; RITANSERIN;

EID: 0026500698     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1992.03480080043020     Document Type: Letter

References (5)

1. Atkinson AB. The treatment of Cushing’s syndrome. Clin Endocrinol. 1991;34:507-513.
2. Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PFM, Laduron PM. Receptor-binding properties in vitro and in vivo of ritanserin. Mol Pharmacol. 1985;27:600-611.
3. Awonters F, Niemegeers CJE, Megens AAHP, Meert TF, Janssen PAJ. Pharmacological profile of ritanserin. Drug Develop Res. 1988;15:61-73.
4. Tepavcevic D, Mikulic V, Jelic T, Korsic M, Kozic B, Plavsic V. Effects of the serotonin antagonist ritanserin on the hypothalamic-pituitary function in normal humans. J Endocrinol Invest. 1985;8(suppl 3):93.
5. Sonino N, Fava GA, Grandi S, Mantero F, Boscaro M. Stressful life events in the pathogenesis of Cushing’s syndrome. Clin Endocrinol. 1988;29:617-623.